ValuEngine upgraded shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) from a sell rating to a hold rating in a report issued on Wednesday.

Several other research firms have also issued reports on TBPH. BidaskClub raised Theravance Biopharma from a hold rating to a buy rating in a report on Saturday, June 24th. Cantor Fitzgerald set a $55.00 target price on Theravance Biopharma and gave the stock a buy rating in a report on Wednesday, July 19th. Needham & Company LLC reissued a buy rating on shares of Theravance Biopharma in a report on Wednesday, August 2nd. Zacks Investment Research raised Theravance Biopharma from a sell rating to a hold rating in a report on Tuesday, September 5th. Finally, Evercore ISI assumed coverage on Theravance Biopharma in a research report on Wednesday, August 16th. They set an outperform rating and a $45.00 price objective for the company. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus price target of $41.63.

Theravance Biopharma (TBPH) opened at 32.67 on Wednesday. The company’s market capitalization is $1.76 billion. The company has a 50 day moving average price of $29.80 and a 200-day moving average price of $35.28. Theravance Biopharma has a 12-month low of $23.15 and a 12-month high of $43.44.

TRADEMARK VIOLATION WARNING: “Theravance Biopharma, Inc. (TBPH) Upgraded by ValuEngine to Hold” was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.dailypolitical.com/2017/09/14/theravance-biopharma-inc-tbph-upgraded-by-valuengine-to-hold.html.

In other Theravance Biopharma news, Director Henrietta Fore acquired 6,000 shares of the company’s stock in a transaction that occurred on Friday, August 11th. The stock was acquired at an average cost of $23.99 per share, for a total transaction of $143,940.00. Following the transaction, the director now directly owns 24,000 shares in the company, valued at $575,760. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Frank Pasqualone acquired 4,000 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The shares were acquired at an average price of $26.34 per share, with a total value of $105,360.00. Following the completion of the transaction, the senior vice president now owns 213,180 shares in the company, valued at $5,615,161.20. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 20,000 shares of company stock valued at $494,300. 6.10% of the stock is owned by corporate insiders.

Hedge funds have recently made changes to their positions in the stock. QS Investors LLC bought a new stake in shares of Theravance Biopharma during the 2nd quarter worth $100,000. Ameritas Investment Partners Inc. raised its position in Theravance Biopharma by 1,494.3% in the first quarter. Ameritas Investment Partners Inc. now owns 3,635 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 3,407 shares during the last quarter. Aperio Group LLC bought a new position in Theravance Biopharma in the second quarter valued at about $205,000. BNP Paribas Arbitrage SA raised its position in Theravance Biopharma by 570.7% in the second quarter. BNP Paribas Arbitrage SA now owns 5,151 shares of the biopharmaceutical company’s stock valued at $205,000 after purchasing an additional 4,383 shares during the last quarter. Finally, Amalgamated Bank bought a new position in Theravance Biopharma in the second quarter valued at about $214,000. Institutional investors and hedge funds own 84.54% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.